Osung Kwon1, Soo-Jin Kang1, Se Hun Kang1, Pil Hyung Lee1, Sung-Cheol Yun1, Jung-Min Ahn1, Duk-Woo Park1, Seung-Whan Lee1, Young-Hak Kim1, Cheol Whan Lee1, Ki Hoon Han1, Seong-Wook Park1, Seung-Jung Park2. 1. From the Department of Cardiology (O.K., S.-J.K., S.H.K., P.H.L., J.-M.A., D.-W.P., S.-W.L., Y.-H.K., C.W.L., K.H.H., S.-W.P., S.-J.P.) and Department of Biostatistics (S.-C.Y.), University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. 2. From the Department of Cardiology (O.K., S.-J.K., S.H.K., P.H.L., J.-M.A., D.-W.P., S.-W.L., Y.-H.K., C.W.L., K.H.H., S.-W.P., S.-J.P.) and Department of Biostatistics (S.-C.Y.), University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. sjpark@amc.seoul.kr.
Abstract
BACKGROUND: The mechanism of statin for atheroma stabilization remains unclear. We aimed to assess the relationship between on-treatment changes in serum inflammatory biomarker levels and plaque composition in differed nonculprit coronary lesions. METHODS AND RESULTS: The changes in serum biochemical values, and intravascular ultrasound data were evaluated in 218 patients with virtual histology (VH)-intravascular ultrasound-defined fibroatheroma-containing segments after 12-month rosuvastatin treatment. When stratifying patients into quartiles according to the change in high-sensitivity C-reactive protein (hsCRP), there was a significant positive linear relationship for the changes in %necrotic core (coefficient, 1.31; standard error, 0.54) and %dense calcium volumes (coefficient, 0.80; standard error, 0.27), but a negative linear relationship for the changes in %fibrous (coefficient, -0.94; standard error, 0.45) and %fibrofatty volumes (coefficient, -1.17; standard error, 0.56; all P<0.05). The decrease in hsCRP (-1.2±3.9 versus 0.5±3.4 mg/L; P=0.02) was greater in those without VH-defined thin-cap fibroatheroma (TCFA, defined as >30° of necrotic core abutting the lumen in 3 consecutive slices) than those with VH-TCFA at follow-up. Diabetes mellitus, a larger normalized total atheroma volume, and the presence of VH-TCFA at baseline predicted the presence of VH-TCFA at follow-up (odds ratio, 4.01, 1.18, and 9.21, respectively; all P<0.05), whereas the change in hsCRP showed a trend (odds ratio, 1.19; P=0.07). The change in low-density lipoprotein-cholesterol had no relationship with the changes in hsCRP or plaque compositions. CONCLUSIONS: With 12-month rosuvastatin therapy, a greater hsCRP reduction (not low-density lipoprotein-cholesterol) was associated with a greater decrease in %necrotic core volume and the absence of VH-TCFA, indicating a link between the anti-inflammatory action of statin and plaque stabilization by reducing NC and reinforcing fibrous cap. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT00997880.
RCT Entities:
BACKGROUND: The mechanism of statin for atheroma stabilization remains unclear. We aimed to assess the relationship between on-treatment changes in serum inflammatory biomarker levels and plaque composition in differed nonculprit coronary lesions. METHODS AND RESULTS: The changes in serum biochemical values, and intravascular ultrasound data were evaluated in 218 patients with virtual histology (VH)-intravascular ultrasound-defined fibroatheroma-containing segments after 12-month rosuvastatin treatment. When stratifying patients into quartiles according to the change in high-sensitivity C-reactive protein (hsCRP), there was a significant positive linear relationship for the changes in %necrotic core (coefficient, 1.31; standard error, 0.54) and %dense calcium volumes (coefficient, 0.80; standard error, 0.27), but a negative linear relationship for the changes in %fibrous (coefficient, -0.94; standard error, 0.45) and %fibrofatty volumes (coefficient, -1.17; standard error, 0.56; all P<0.05). The decrease in hsCRP (-1.2±3.9 versus 0.5±3.4 mg/L; P=0.02) was greater in those without VH-defined thin-cap fibroatheroma (TCFA, defined as >30° of necrotic core abutting the lumen in 3 consecutive slices) than those with VH-TCFA at follow-up. Diabetes mellitus, a larger normalized total atheroma volume, and the presence of VH-TCFA at baseline predicted the presence of VH-TCFA at follow-up (odds ratio, 4.01, 1.18, and 9.21, respectively; all P<0.05), whereas the change in hsCRP showed a trend (odds ratio, 1.19; P=0.07). The change in low-density lipoprotein-cholesterol had no relationship with the changes in hsCRP or plaque compositions. CONCLUSIONS: With 12-month rosuvastatin therapy, a greater hsCRP reduction (not low-density lipoprotein-cholesterol) was associated with a greater decrease in %necrotic core volume and the absence of VH-TCFA, indicating a link between the anti-inflammatory action of statin and plaque stabilization by reducing NC and reinforcing fibrous cap. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT00997880.
Authors: Kyoung Min Kim; Kyong Yeun Jung; Han Mi Yun; Seo Young Lee; Tae Jung Oh; Hak Chul Jang; Soo Lim Journal: Cardiovasc Diabetol Date: 2017-11-09 Impact factor: 9.951
Authors: Massimiliano Ruscica; Alberto Corsini; Nicola Ferri; Maciej Banach; Cesare R Sirtori Journal: Pharmacol Res Date: 2020-05-20 Impact factor: 7.658
Authors: Tomas Kovarnik; Zhi Chen; Gary S Mintz; Andreas Wahle; Kristyna Bayerova; Ales Kral; Martin Chval; Karel Kopriva; John Lopez; Milan Sonka; Ales Linhart Journal: Cardiovasc Diabetol Date: 2017-12-07 Impact factor: 9.951
Authors: Aakriti Gupta; Mahesh V Madhavan; Timothy J Poterucha; Ersilia M DeFilippis; Jessica A Hennessey; Bjorn Redfors; Christina Eckhardt; Behnood Bikdeli; Jonathan Platt; Ani Nalbandian; Pierre Elias; Matthew J Cummings; Shayan N Nouri; Matthew Lawlor; Lauren S Ranard; Jianhua Li; Claudia Boyle; Raymond Givens; Daniel Brodie; Harlan M Krumholz; Gregg W Stone; Sanjum S Sethi; Daniel Burkhoff; Nir Uriel; Allan Schwartz; Martin B Leon; Ajay J Kirtane; Elaine Y Wan; Sahil A Parikh Journal: Res Sq Date: 2020-08-11
Authors: Karina Di Gregoli; Michelle Somerville; Rosaria Bianco; Anita C Thomas; Aleksandra Frankow; Andrew C Newby; Sarah J George; Christopher L Jackson; Jason L Johnson Journal: Arterioscler Thromb Vasc Biol Date: 2020-04-16 Impact factor: 8.311
Authors: Kikkie Poels; Suzanne I M Neppelenbroek; Marie José Kersten; M Louisa Antoni; Esther Lutgens; Tom T P Seijkens Journal: J Immunother Cancer Date: 2021-06 Impact factor: 13.751